Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)

What we doOur approachPipelineTechnologyPublications
About usExecutive ManagementBoard of DirectorsScientific Advisory Board
News & eventsPress releasesEventsInterviews
Investors
Careers

Back
Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML)
 8:00:00 AM

Keep reading
Mendus to present novel data supporting the broad potential of its proprietary cancer vaccine platform at CICON23Read